Patient-reported symptoms and signs in patients with moderate-severe plaque psoriasis treated with guselkumab or adalimumab: Results from VOYAGE 1, a phase III clinical trial

Background: Guselkumab, a selective IL-23 blocker, is highly efficacious for treating psoriasis (PsO). Patient-reported symptoms & signs were evaluated in PsO patients treated with GUS or adalimumab (ADA).

http://ift.tt/2sXAQG2